{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T05:33:55Z","timestamp":1782192835056,"version":"3.54.5"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.lungcan.2023.107427","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T13:56:39Z","timestamp":1700661399000},"page":"107427","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study"],"prefix":"10.1016","volume":"187","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8268-8368","authenticated-orcid":false,"given":"A.","family":"Schuler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Huser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sch\u00e4r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Scherz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Gautschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Mauti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"von Briel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Waibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Wannesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Pankovics","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.T.","family":"Mark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.I.","family":"Rothschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Addeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.D.","family":"Janthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Siano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Boos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Britschgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fr\u00fch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"48","key":"10.1016\/j.lungcan.2023.107427_b0005","doi-asserted-by":"crossref","first-page":"78985","DOI":"10.18632\/oncotarget.12587","article-title":"The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.lungcan.2023.107427_b0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40291-021-00563-1","article-title":"Worldwide prevalence of epidermal growth factor receptor mutations in non-small cell lung cancer: a meta-analysis","volume":"26","author":"Melosky","year":"2022","journal-title":"Mol. Diagn. Ther."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107427_b0015","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107427_b0020","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1186\/s12885-019-5820-0","article-title":"EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer","volume":"19","author":"Fang","year":"2019","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2023.107427_b0025","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.19.00931","article-title":"Osimertinib for patients with non-small-cell lung cancer harboring uncommon EGFR mutations: a multicenter, open-label, phase II trial (KCSG-LU15-09)","volume":"38","author":"Cho","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2023.107427_b0030","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2217\/fon-2021-0892","article-title":"Uncommon EGFR mutations conducted with osimertinib in patients with NSCLC: a study protocol of phase 2 study (UNICORN\/TCOG1901)","volume":"18","author":"Okuma","year":"2022","journal-title":"Future Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2023.107427_b0035","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.annonc.2022.02.225","article-title":"Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)","volume":"33","author":"Janning","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2023.107427_b0040","doi-asserted-by":"crossref","unstructured":"Planchard D, Popat S, Kerr K et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29 (Suppl 4): iv192-iv237.","DOI":"10.1093\/annonc\/mdy275"},{"key":"10.1016\/j.lungcan.2023.107427_b0045","unstructured":"D.S.W. Ettinger, D.E. Aisner, D.L. Akerley, W. Bauman, J.R. Bharat, et al., NCCN Guidelines, Non-Small Cell Lung Cancer Version 1.2023-December 22, 2022. 2023. www.nccn.org\/patients 2023."},{"issue":"12","key":"10.1016\/j.lungcan.2023.107427_b0050","doi-asserted-by":"crossref","first-page":"4998","DOI":"10.21037\/jtd-22-536","article-title":"Oligoprogression in non-small cell lung cancer: a narrative review","volume":"14","author":"Nguyen","year":"2022","journal-title":"J. Thorac. Dis."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107427_b0055","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a european society for radiotherapy and oncology and european organisation for research and treatment of cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2023.107427_b0060","series-title":"Essentials of clinical radiation oncology","author":"Sittenfeld","year":"2021"},{"key":"10.1016\/j.lungcan.2023.107427_b0065","article-title":"Oligometastatic disease classification","author":"Esmo","year":"2020","journal-title":"Oligometastatic-Disease-Classification. 2023"},{"issue":"1","key":"10.1016\/j.lungcan.2023.107427_b0070","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2023.107427_b0075","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nrclinonc.2011.44","article-title":"Oligometastases revisited","volume":"8","author":"Weichselbaum","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2023.107427_b0080","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.cllc.2014.04.003","article-title":"An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer","volume":"15","author":"Ashworth","year":"2014","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2023.107427_b0085","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.lungcan.2019.02.020","article-title":"Patterns of progression on osimertinib in EGFR T790M positive NSCLC: a Swiss cohort study","volume":"130","author":"Schmid","year":"2019","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2023.107427_b0090","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1016\/j.cllc.2018.09.010","article-title":"Efficacy of local consolidative therapy for oligometastatic lung adenocarcinoma patients harboring epidermal growth factor receptor mutations","volume":"20","author":"Hu","year":"2019","journal-title":"Clin. Lung Cancer"},{"issue":"9","key":"10.1016\/j.lungcan.2023.107427_b0095","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2023.107427_b0100","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.21037\/jtd.2019.08.30","article-title":"Mechanisms of resistance to osimertinib","volume":"12","author":"Lazzari","year":"2020","journal-title":"J. Thorac. Dis."},{"issue":"4","key":"10.1016\/j.lungcan.2023.107427_b0105","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.annonc.2020.01.013","article-title":"TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer","volume":"31","author":"Oxnard","year":"2020","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2023.107427_b0110","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2217\/fon-2021-1406","article-title":"INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance","volume":"18","author":"Fs","year":"2022","journal-title":"Future Oncol."},{"key":"10.1016\/j.lungcan.2023.107427_b0115","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.lungcan.2020.07.014","article-title":"Mechanisms of osimertinib resistance and emerging treatment options","volume":"147","author":"Schmid","year":"2020","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2023.107427_b0120","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.jtho.2019.07.027","article-title":"Capmatinib and osimertinib combination therapy for EGFR-mutant lung adenocarcinoma","volume":"15","author":"Gautschi","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2023.107427_b0125","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.jtho.2018.05.019","article-title":"Consolidative local ablative therapy improves the survival of patients with synchronous oligometastatic NSCLC harboring EGFR activating mutation treated with first-line EGFR-TKIs","volume":"13","author":"Xu","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2023.107427_b0130","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jtho.2021.09.014","article-title":"IMpower150 final exploratory analyses for atezolizumab plus bevacizumab and chemotherapy in key NSCLC patient subgroups with EGFR mutations or metastases in the liver or brain","volume":"17","author":"Nogami","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2023.107427_b0135","doi-asserted-by":"crossref","first-page":"302","DOI":"10.21037\/tlcr.2019.04.12","article-title":"Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment","volume":"8","author":"Zhang","year":"2019","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.lungcan.2023.107427_b0140","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.lungcan.2017.11.005","article-title":"A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer","volume":"114","author":"Tu","year":"2017","journal-title":"Lung Cancer"},{"issue":"8","key":"10.1016\/j.lungcan.2023.107427_b0145","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1002\/ijc.33904","article-title":"Overall survival benefit of osimertinib and clinical value of upfront cranial local therapy in untreated EGFR-mutant nonsmall cell lung cancer with brain metastasis","volume":"150","author":"Zhao","year":"2022","journal-title":"Int. J. Cancer"},{"issue":"33","key":"10.1016\/j.lungcan.2023.107427_b0150","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1200\/JCO.2018.78.3118","article-title":"CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"36","author":"Reungwetwattana","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.lungcan.2023.107427_b0155","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non\u2013small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"34","key":"10.1016\/j.lungcan.2023.107427_b0160","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1200\/JCO.2015.61.8918","article-title":"Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT): a randomized, double-blind phase III trial","volume":"33","author":"Kelly","year":"2015","journal-title":"J. Clin. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223009650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223009650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:05:54Z","timestamp":1759237554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500223009650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":32,"alternative-id":["S0169500223009650"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107427","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107427","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107427"}}